NEW YORK, June 30, 2015 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities CorMedix, Inc. ("CorMedix" or the "Company") (NYSE MKT: CRMD -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.

The investigation concerns whether CorMedix and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On June 29, 2015, The Pump Stopper published on SeekingAlpha.com a report on CorMedix alleging, among other things, that: (i) CorMedix is based on a 1970s-era catheter product acquired for less than $1 million in a bankruptcy sale, apparently after at least two failed sales processes; (ii) CorMedix's market size claims are greatly exaggerated; and (iii) CorMedix is touting misleading clinical-data, as in-depth industry research shows its Neutrolin/Taurolidine product is a failure and "40% benefit!" versus industry standards is inaccurate.

Following this news shares of CorMedix fell $0.81 or 16.67% to close at $4.05 on June 29, 2015.

If you are aware of any facts relating to this investigation, or purchased shares of CorMedix, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-cormedix-inc-300106751.html

SOURCE Bronstein, Gewirtz & Grossman, LLC